Robert W. Baird Has Lowered Expectations for Avantor (NYSE:AVTR) Stock Price

Avantor (NYSE:AVTR) had its target price trimmed by Robert W. Baird from $27.00 to $26.00 in a report issued on Monday, Benzinga reports. The brokerage currently has an outperform rating on the stock.

Other equities research analysts have also issued reports about the company. Wells Fargo & Company started coverage on Avantor in a research note on Tuesday, August 27th. They set an “overweight” rating and a $30.00 price target for the company. Evercore ISI dropped their target price on shares of Avantor from $28.00 to $27.00 and set an “outperform” rating for the company in a research report on Tuesday, July 2nd. Citigroup cut shares of Avantor from a “buy” rating to a “neutral” rating and reduced their price target for the company from $30.00 to $23.00 in a research report on Wednesday, July 10th. TD Cowen increased their price objective on shares of Avantor from $28.00 to $31.00 and gave the stock a “buy” rating in a research report on Monday, July 29th. Finally, Morgan Stanley lifted their target price on shares of Avantor from $28.00 to $29.00 and gave the company an “overweight” rating in a report on Monday, July 29th. Three analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, Avantor has an average rating of “Moderate Buy” and an average target price of $27.57.

Avantor Stock Down 0.3 %

Shares of AVTR opened at $22.45 on Monday. The firm has a market cap of $15.25 billion, a PE ratio of 57.56, a price-to-earnings-growth ratio of 2.93 and a beta of 1.33. The company has a quick ratio of 1.05, a current ratio of 1.59 and a debt-to-equity ratio of 0.89. The company’s fifty day moving average is $25.32 and its two-hundred day moving average is $24.21. Avantor has a fifty-two week low of $17.06 and a fifty-two week high of $28.00.

Insider Buying and Selling at Avantor

In other news, CAO Steven W. Eck sold 3,525 shares of the business’s stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $25.06, for a total value of $88,336.50. Following the completion of the sale, the chief accounting officer now owns 29,544 shares of the company’s stock, valued at approximately $740,372.64. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Graypoint LLC raised its position in shares of Avantor by 3.8% during the 1st quarter. Graypoint LLC now owns 11,414 shares of the company’s stock valued at $292,000 after acquiring an additional 423 shares in the last quarter. Intech Investment Management LLC increased its stake in Avantor by 1.8% during the second quarter. Intech Investment Management LLC now owns 29,068 shares of the company’s stock valued at $616,000 after purchasing an additional 514 shares during the last quarter. Arizona State Retirement System raised its holdings in shares of Avantor by 0.3% during the second quarter. Arizona State Retirement System now owns 186,567 shares of the company’s stock worth $3,955,000 after purchasing an additional 528 shares during the period. Veracity Capital LLC lifted its position in shares of Avantor by 1.0% in the 3rd quarter. Veracity Capital LLC now owns 52,359 shares of the company’s stock worth $1,355,000 after buying an additional 543 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Avantor by 2.8% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 26,921 shares of the company’s stock valued at $571,000 after buying an additional 733 shares during the period. Institutional investors and hedge funds own 95.08% of the company’s stock.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.